Table 2.
Factors associated with low (<2000 IU/mL) or high level (≥2000 IU/mL) of hepatitis B viremia after discontinuation of therapy
| Low viral load relapser | High viral load relapser | P value | ||
|---|---|---|---|---|
| Age | Mean ± SD (years) | 40.9 ± 6.0 | 47.4 ± 14.2 | 0.103 |
| Age (years) | ≤45 | 13 (81.3 %) | 18 (47.4 %) | 0.021 |
| >45 | 3 (18.7 %) | 20 (52.6 %) | ||
| Gender | Male | 9 (56.3 %) | 24 (63.2 %) | 0.634 |
| Race | Asian | 16 (100.0 %) | 35 (92.1 %) | 0.247 |
| Baseline HBV DNA level (log10) | Mean ± SD (IU/mL) | 7.41 ± 7.56 (n = 15) | 7.85 ± 8.15 (n = 32) | 0.561 |
| Prior treatment | None | 13 (81.3 %) | 20 (52.6 %) | 0.003 |
| Drug | ETV | 14 (87.5 %) | 16 (42.1 %) | 0.009 |
| TDF | 2 (12.5 %) | 21 (55.3 %) | ||
| ETV/TDF | 0 (0.0 %) | 1 (2.6 %) | ||
| Interval to negativity | Mean ± SD (mo) | 13.0 ± 8.1 (n = 15) | 11.4 ± 7.5 (n = 37) | 0.592 |
| Consolidation | <12 months | 7 (43.8 %) | 12 (31.6 %) | 0.392 |
| ≥12 months | 9 (56.2 %) | 26 (68.4 %) | ||
| Consolidation | <24 months | 11 (68.8 %) | 32 (84.2 %) | 0.198 |
| ≥24 months | 5 (31.2 %) | 6 (15.8 %) | ||
| Duration of Rx | Mean ± SD (mo) | 39.8 ± 17.7 (n = 16) | 37.0 ± 17.9 (n = 38) | 0.895 |
| Time to relapse | Mean ± SD (mo) | 8.3 + 7.1 (n = 13) | 4.4 + 3.5 (n = 37) | 0.026 |